草稿:B-cell therapy for tumors

Stimulating B cells to produce specific homologous neutralizing-antibodies using for the targeted treatment of tumors is a novel tumor treatment strategy proposed by Dr. Zheng Liu from Guilin Medical University [1]. In a healthy body, when tumor cells emerge, they gradually adapt and evade the body's immune system. Tumors will form when the number of tumor cells surpasses a certain threshold. The transformation of normal cells into tumor cells within the body is a complex process. It involves mutations in multiple genes and the production of mutated proteins. Throughout this process, proteins in tumor cells accumulate various mutations constantly. The surface of tumor cells may expose different epitopes of mutated proteins at various stages, or even randomly expose mutated protein epitopes. As a result, current approaches to targeted therapies are evidently less effective in treating tumors.

However, for a normal and healthy body, mutated proteins in tumor cells are as easy to distinguish as invading viruses. Based on this theory, tumor cells from different stages of mice are injected into the body of healthy mice. This leads to the production of specific homologous antibodies that target different stages of mutated proteins or different epitopes of mutated proteins. These antibodies are then injected back into the mice with tumors, gradually killing the tumor cells with antibody neutralization therapy until they fall below the threshold, thereby completely eliminating the tumor. Nevertheless, due to the fact that a mutated protein in tumor cells may randomly expose different epitopes, stimulating the production of dozens or even hundreds of different epitope antibodies, it is currently impossible to distinguish these antibodies individually. Despite this, this tumor treatment strategy has proven highly effective in treating mouse cubanus squamous cell carcinoma (mCSCC). The experiment was structured into three phases:

1. Isolation and Culture: mCSCC cells were isolated and cultured from DMBA/TPA-induced mCSCC.

2. Antibody Production: The proliferated tumor cells were subsequently injected into healthy mice to generate anti-tumor homologous neutralizing antibodies.

3. Serum Treatment: Therapeutic serum was harvested from the healthy mice and reintroduced into the mice with tumors.

The findings of this research were published in the eLife journal on April 16, 2024 [1]. This research allows us to speculate if other tumor cells can also be isolated, cultured, and subsequently reinfused to generate specific homologous antibodies, thereby achieving the objective of tumor treatment. However, more comprehensive research is required before we can proceed with human trials for the clinical treatment of tumors. To conclude, Dr. Zheng Liu's innovative theory and methodology of B-cell therapy for tumors have pioneered a new field in cancer treatment and unveiled fresh possibilities for combating cancer.

1. Liu Zheng. Generating specific homologous neutralizing-antibodies: a novel therapeutic strategy in cancer treatment. 2024, eLife13:RP95678. https://doi.org/10.7554/eLife.95678.1